Q1 2027 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Glenmark Pharmaceuticals Ltd (BOM:532296) delivered a strong consolidated revenue growth of 23.1% YoY, with broad-based growth across all key markets.
- The India formulation business outperformed the IPM significantly, recording 18.1% growth in Q1, driven by strong performance in core therapies and successful launches like TEVIMBRA and BRUKINSA.
- The North America business saw a strong recovery with 41.1% YoY growth, driven by respiratory launches and a robust pipeline of new product approvals.
- The global innovative portfolio is advancing well, with RYALTRIS growing over 40% in secondary sales and WINLEVI expanding into new European markets.
- The company maintains a strong balance sheet with a gross debt zero position and is on track to achieve its margin guidance of 21-22% for the full year.
- The ongoing geopolitical situation is increasing API and logistics costs, which is putting pressure on gross margins and overall operating profitability.
- The Europe business recorded muted growth of 11.9% in Q1, with management guiding to only high single-digit growth for the year as it transforms its portfolio.
- The company is facing increased operating costs due to reinvestments in the base business and preparations for new product launches, impacting margins.
- The injectable portfolio in the US is still in early stages and will take time to meaningfully contribute to revenue, with differentiated products only expected to contribute next year.
- There is uncertainty regarding the development of ISB 830 with partner BioCryst, as the company has no visibility into their next steps for the asset.
Ladies and gentlemen, good day and welcome to Q1 F527 earnings conference call of Glenmark Pharmaceutical Limited. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Utkarsh Gandhi, Senior General Manager, Invest Relations of Glenmark Pharmaceuticals.
Thank you and over to you Mr. Utkarsh.
Thank you, Renju. Good morning, everyone, and welcome to the Q1 FY27 earnings conference call of Glenmark Pharmaceuticals Limited. Before we start the Q&A, let us quickly review the performance of the business in the first quarter.
For the first quarter of FY27, Glenmark's consolidated revenue from operations was at INR40,185 million as against INR32,644 million in the corresponding quarter last year recording YoY growth of 23.1%.
Quickly covering our key regions starting with India, sales from the formulation business in India for the first quarter of FY27 was at INR14,321 million as against
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
